Tetracycline

Overview

Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells. The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.

Indication

Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.

Associated Conditions

Acinetobacter Infections
Actinomycosis
Anthrax
Bacterial Infections
Bartonellosis
Brucellosis
Campylobacter Infection
Chancroid
Chlamydial Infections
Cholera (Disorder)
Clostridium Infections
Conjunctivitis, Inclusion
Cystitis
Endometritis
Entamoebic histolytica infection
Escherichia infections
Granuloma Inguinale
Helicobacter Pylori Infection
Infection
Infection, Bacteroides
Klebsiella Infections
Listeria infection
Lower respiratory tract infection bacterial
Lymphogranuloma Venereum
Necrotizing ulcerative gingivostomatitis
Neisseria Gonorrhoeae Infection
Nephritis
Ornithosis
Plague
Prostatitis
Psittacosis
Q Fever
Relapsing Fever
Rickettsialpox
Rocky Mountain Spotted Fever
Rosacea
Severe Acne
Shigella Infection
Skin Infections caused by Staphylococcus Aureus
Skin and Subcutaneous Tissue Bacterial Infections
Syphilis
Trachoma
Tularemia
Typhus
Upper respiratory tract infection bacterial
Urinary Tract Infection
Yaws
Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection

Clinical Trials

View More Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.	2022/06/27	NCT05432115	Phase 4	Recruiting	Shandong University
Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses	2022/06/24	NCT05431075	Phase 4	Completed	Shandong University
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment	2022/02/22	NCT05250050	Phase 4	UNKNOWN	Shanghai Zhongshan Hospital
Tetracycline Treatment Tolerability Trial	2022/02/02	NCT05219929	Phase 2	ENROLLING_BY_INVITATION	Johns Hopkins University
Helicobacter Pylori Eradication and Follow-up	2021/09/30	NCT05061732	Phase 4	Recruiting	Shanghai Zhongshan Hospital
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication	2021/09/20	NCT05049902	Phase 4	Completed	Shandong University
Tetracycline Versus Doxycycline for HP Rescue Therapy	2021/08/24	NCT05018923	Phase 4	UNKNOWN	Shanghai Zhongshan Hospital
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	2021/05/25	NCT04901117	Phase 4	UNKNOWN	Shandong University
The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure	2021/03/23	NCT04810793	N/A	Completed	Shandong University
Predictive Factors Affecting the Efficacy of Local Tetracycline Injection for Treatment of Post-mastectomy Seroma.	2021/01/29	NCT04730674	Not Applicable	Completed	Zagazig University

FDA Drug Approvals

View More FDA Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Tetracycline Hydrochloride	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-767	ORAL	500 mg in 1 1	3/31/2020
Tetracycline Hydrochloride	Rebel Distributors Corp	21695-640	ORAL	500 mg in 1 1	1/13/2010
Tetracycline Hydrochloride	Rebel Distributors Corp	21695-302	ORAL	250 mg in 1 1	1/13/2010
Tetracycline Hydrochloride	Actavis Pharma, Inc.	0591-2474	ORAL	250 mg in 1 1	11/30/2018
Tetracycline Hydrochloride	Breckenridge Pharmaceutical, Inc.	51991-907	ORAL	500 mg in 1 1	2/8/2024
TETRACYCLINE HYDROCHLORIDE	Strides Pharma Science Limited	64380-891	ORAL	500 mg in 1 1	10/21/2022
Tetracycline Hydrochloride	Amneal Pharmaceuticals NY LLC	69238-1522	ORAL	250 mg in 1 1	12/30/2023
Tetracycline	Aspen Veterinary Resources	46066-256	ORAL	324 g in 2.27 kg	8/20/2025
Pylera	Physicians Total Care, Inc.	54868-6151	ORAL	125 mg in 1 1	3/14/2011
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE	H2-Pharma, LLC	61269-385	ORAL	125 mg in 1 1	5/31/2023

EMA Drug Approvals

View More EMA Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

View More Health Canada Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
TETRACYCLINE 1% OPHTHALMIC OINTMENT	steri-med pharma inc.	00792594	Ointment - Ophthalmic	10 MG / G	12/31/1988
TETRACYN CAP 250MG	Pfizer Canada Ulc	00024422	Capsule - Oral	250 MG / CAP	12/31/1952
NOVO-TETRA 250MG	novopharm limited	00021806	Tablet - Oral	250 MG	12/31/1967
ACHROMYCIN ONT OPH 1%	lederle cyanamid canada inc.	00015083	Ointment - Ophthalmic	1 %	12/31/1955
PYLERA	laboratoires juvise pharmaceuticals	02246962	Capsule - Oral	125 MG	N/A
JAA TETRA TAB 250MG	jaapharm canada inc.	00889393	Tablet - Oral	250 MG	12/31/1993

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access